CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease...
Phase 2
Arlington, Virginia, United States and 21 other locations
will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney...
Phase 3
Baltimore, Maryland, United States and 12 other locations
is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney...
Phase 3
Washington, District of Columbia, United States and 17 other locations
This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and...
Phase 2
Woodbridge, Virginia, United States of America and 43 other locations
The main objective of this study is to evaluate the safety, efficacy and pharmacokinetics of paricalcitol oral solution in pediatric participants of...
Phase 3
Washington, District of Columbia, United States and 12 other locations
The purpose of this study is to determine whether vonsetamig will safely decrease anti-HLA antibodies to allow for kidney transplantation.Vo...
Phase 1, Phase 2
Baltimore, Maryland, United States and 8 other locations
and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney...
Phase 3
Fairfax, Virginia, United States and 319 other locations
To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV)* To characterize the pharmacokinetic (PK) properties of RGLS...
Phase 1
Baltimore, Maryland, United States and 27 other locations
to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...
Phase 3
Alexandria, Virginia, United States and 295 other locations
of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys...
Phase 3
Takoma Park, Maryland, United States and 55 other locations
Clinical trials
Research sites
Resources
Legal